medication. A small proportion of individuals switched shortly to SB4 and then later to other medication. 5.7% of former etanercept users switched to other medication at the time of Switch date. For details, see Figure 1. Many patients switched back and forth several times, also using other medication at short time intervals. The method of distribution (pen versus injection) was associated with higher odds for being switched. Patients using etanercept pen were more likely to switch to biosimilar etanercept after BE (Figure 2).

For patients who switched to SB4 the 18 months cumulative incidence of drug survival was 72%, 95%CI [65-79]%. At 2 years follow-up the drug survival in switchers will be matched with historic drug survival rate of etanercept estimated using data from NorPD.

Conclusion: The Norwegian Prescription Database is a useful tool that enables us to monitor use, changes and trends in use of selected drugs. A longer follow-up is warranted in order to describe drug survival after switch from etanercept to biosimilar etanercept. However, close collaboration between pharmacists, clinicians and statisticians is warranted.

Objectives: We used data from the RISE registry to perform a cross-sectional analysis among U.S. rheumatologists of prescription patterns for biologic DMARDs and tocilizumab and their relationship to RA disease activity.

Methods: RISE is a U.S. registry that passively collects data on all patients seen by participating practices, thereby reducing selection bias present in single-insurer claims databases. As of December 2017, RISE held validated data from 1,257 providers in 236 practices, representing an estimated 25% of the U.S. clinical rheumatology workforce. We identified patients with available demographic and disease activity information who were assigned ≥2 codes for RA >30 days apart between January and December 2017. Practices with <20 RA patients (15/104 practices providing all necessary data) were excluded. We tallied the proportion of patients in each practice prescribed a TNF inhibitor, abatacept, rituximab, tocilizumab, or tocilizumab at least once during 2017. Patients prescribed >1 of these drugs were assigned to the first drug prescribed and therefore counted only once. We used a hierarchical linear model to predict the probability of receiving a prescription for a biologic based on the patient’s most recent disease activity score (moderate or high disease activity vs. low disease activity or remission) and age from 2016, accounting for clustering by practice.

Results: We analyzed 53,850 patients from 104 practices. Overall, 29% of patients were prescribed a biologic DMARD or tocilizumab in 2017. TNF inhibitors were most commonly prescribed, followed by abatacept (4.5% of patients), tocilizumab (4.2%), tocilizumab (3.4%), and rituximab (2.5%). We found significant variation within practices in the proportion of patients prescribed any of these drugs (range 0%-100%). In the adjusted analysis, we found that patients with higher disease activity in 2016 were more likely to receive biologics in 2017 (OR 1.56, 95% CI (1.51, 1.62)). Within a practice, as shown in the figure, the risk-adjusted likelihood of receiving a biologic prescription still showed significant variation (between 0%-83% of patients in each practice received a biologic; model c-statistic 0.61).

Conclusion: In this large sample of U.S. rheumatology practices, higher RA disease activity correlated with the likelihood that a patient would receive a prescription for a biologic, but did not account for all of the variability in biologic prescription patterns. These results suggest that there may be other factors in addition to RA disease activity that account for practice-to-practice variability in biologic prescription patterns. Disclainer: These data were collected from the ACR’s RISE Registry; however, the views expressed represent those of the authors, not necessarily those of the ACR.


Disclosure of Interests: Milada Cvanacarova Smallstuen Grant/research support from: I have received a Research grant from Pfizer, Randeep Madia Employee of: Pfizer, still employed, Oddvar Solli Employee of: Pfizer, still employed by Pfizer, Erik Hjervin Employee of: Pfizer, still employed by Pfizer DOI: 10.1136/annrheumdis-2019-eular.5799

Disclosure of Interests: Celine van de Laar,1 Martijn Oude Voshaar2, Walid Fakhouri2, Liliana Zaremba-Pechmann3, Francesco de Leonardis4, Inmaculada De La Torre5, Mart van de Laar1,2,6,7,8, Transparency in Healthcare, Hengelo, Netherlands;2 Eli Lilly and Company, Indianapolis, United States of America;3 Arthritis Center Twente, Enschede, Netherlands

Background: Treating Rheumatoid Arthritis (RA) to an a priori defined disease activity target (T2T) is recommended in EULAR guidelines. This involves a step-up approach in which it is first attempted to achieve the target with a combination of conventional synthetic (cs) DMARDs. Baricitinib is a JAK1/JAK2-inhibitor approved for treatment of patients suffering from RA. EULAR and ACR guidelines currently position JAK1/JAK2-inhibitors and bDMARDs at the same level in the therapeutic treatment sequence for csDMARD Inadequate Responders (IR). Cost-effectiveness assessment of different T2T strategies, especially one...